Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-01-04

Clinical Trial Update: Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab [Phase 3]

View source ↗

Summary

Phase 3 trial update on efficacy and safety of secukinumab for palmoplantar pustular psoriasis with completed status and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Palmoplantar Pustular Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2019-01-04